# Trade Mark Journal No.2026/027 3 July 2026

## WO0000001923528 (5,36,41,44)

Office of origin: United States of America

Date of International Registration:27 February 2026
Date of designation in the UK: 27 February 2026

International priority date claimed: 23 February 2026 (United States of America) (99666317)
International priority date claimed: 23 February 2026 (United States of America) (99666330)
International priority date claimed: 23 February 2026 (United States of America) (99666334)
International priority date claimed: 24 February 2026 (United States of America) (99668507)

Class 5
  Pharmaceutical preparations and substances, biological preparations and substances, therapeutic preparations and substances, namely, nucleic acid-targeted therapeutics; pharmaceutical preparations and substances for the treatment of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; biological preparations and substances for the treatment of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; therapeutic preparations and substances for the treatment of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders.
Class 36
  Providing financial information regarding patient reimbursement for pharmaceutical preparations and substances, biological preparations and substances, and therapeutic preparations and substances; financial and insurance consultation services relating to healthcare; patient advisory, support and consultancy services regarding patient finances, insurance and financing of medical treatment; providing financial information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation services relating to patient medical and pharmaceutical insurance and financing; financial advice relating to medical insurance and pharmaceutical access assisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; financial assistance of patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costs.
Class 41
  Education and training services in the field of healthcare; education and training services in the field of pharmaceuticals; education and training services in the field of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders.
Class 44
  Medical and healthcare services; providing medical information, healthcare information and information about pharmaceuticals, biological therapies and therapeutics; providing healthcare and medical information regarding patient access to pharmaceuticals, biologics, and therapeutics, and safe and appropriate use and distribution of pharmaceuticals, biologics, and therapeutics; provision of healthcare information relating to autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; patient advisory, support and consultancy services relating to healthcare, pharmaceuticals, biological therapies and therapeutics; patient medical advisory, support and consultancy services regarding access to medical treatment of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; medical consulting services in the field of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; providing medical and healthcare information in the field of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; providing medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the field of autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders; collecting medical and clinical data and information on autosomal dominant, autosomal recessive, genetic, cardiovascular, neurologic, pulmonary, inflammatory, renal, metabolic, ophthalmologic, and rare diseases and disorders for treatment and diagnostic purposes.

Ionis Pharmaceuticals, Inc.

Representative: Brian J. Focarino Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700,, IP Docketing Department, Washington DC 20004-2400, UNITED STATES OF AMERICA